Literature DB >> 11241140

Carbon dioxide angiography for endovascular grafting in high-risk patients with infrarenal abdominal aortic aneurysms.

J Gahlen1, J Hansmann, H Schumacher, R Seelos, G M Richter, J R Allenberg.   

Abstract

Allergic reactions to contrast media, preexisting renal dysfunction, and hyperthyroidism are relative contraindications for angiography with conventional contrast medium. Carbon dioxide (CO(2)) angiography is an alternative method in high-risk patients because CO(2) is nontoxic, without allergic potential, and not iodic. CO(2)-related complications are extremely rare. Because renal insufficiency often occurs in vascular patients, this method will become increasingly important for endovascular surgery. We report on three consecutive patients with asymptomatic infrarenal aortic aneurysm and concomitant renal dysfunction or allergic reactions to standard contrast media. Aortic stent grafts were deployed under CO(2) angiographic control without complications or worsening of renal function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241140     DOI: 10.1067/mva.2001.111746

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

1.  Complications after endovascular aneurysm repair.

Authors:  Geert Maleux; Marcel Koolen; Sam Heye
Journal:  Semin Intervent Radiol       Date:  2009-03       Impact factor: 1.513

Review 2.  [Clinical requirements of aortic imaging].

Authors:  D Böckler; A Hylik-Dürr; H von Tengg-Kobligk; R Lopez-Benitez; H-U Kauczor; K Klemm
Journal:  Radiologe       Date:  2007-11       Impact factor: 0.635

3.  The Assessment of Carbon Dioxide Automated Angiography in Type II Endoleaks Detection: Comparison with Contrast-Enhanced Ultrasound.

Authors:  Chiara Mascoli; Gianluca Faggioli; Enrico Gallitto; Vincenzo Vento; Giuseppe Indelicato; Rodolfo Pini; Andrea Vacirca; Andrea Stella; Mauro Gargiulo
Journal:  Contrast Media Mol Imaging       Date:  2018-03-26       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.